Ted Yednock Biography and Net Worth

EVP of Annexon

Dr. Yednock joined Annexon Biosciences as Chief Scientific Officer in November 2013. Dr. Yednock was previously Chief Scientific Officer for Prothena Corporation, Head of Research for Elan Pharmaceuticals and a Scientist at Athena Neurosciences. While at Athena, he was the scientific inventor of Tysabri^®, a blockbuster monoclonal antibody for the treatment of multiple sclerosis. In addition to his work in multiple sclerosis, Dr. Yednock has contributed to the invention or progression of numerous drugs in the areas of Alzheimer’s disease, Parkinson’s disease, amyloidosis, rheumatoid arthritis, psoriasis and Crohn’s disease. Dr. Yednock earned his B.S. in biology and chemistry from the University of Illinois and his Ph.D. in anatomy and cell biology from the University of California San Francisco.

What is Ted Yednock's net worth?: The estimated net worth of Ted Yednock is at least $160,571.25 as of October 15th, 2024. Dr. Yednock owns 71,365 shares of Annexon stock worth more than $160,571 as of March 29th. This net worth evaluation does not reflect any other assets that Dr. Yednock may own. Additionally, Dr. Yednock receives an annual salary of $697,760.00 as EVP at Annexon. Learn More about Ted Yednock's net worth.
How old is Ted Yednock?: Dr. Yednock is currently 66 years old. There are 4 older executives and no younger executives at Annexon. Learn More on Ted Yednock's age.
What is Ted Yednock's salary?: As the EVP of Annexon, Inc., Dr. Yednock earns $697,760.00 per year. There are 2 executives that earn more than Dr. Yednock. The highest earning executive at Annexon is Mr. Douglas Love Esq., J.D., CEO, President & Director, who commands a salary of $980,120.00 per year. Learn More on Ted Yednock's salary.
How do I contact Ted Yednock?: The corporate mailing address for Dr. Yednock and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at swheeler@wheelhouselsa.com. Learn More on Ted Yednock's contact information.
Has Ted Yednock been buying or selling shares of Annexon?: Ted Yednock has not been actively trading shares of Annexon during the past quarter. Most recently, Ted Yednock sold 5,408 shares of the business's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $7.41, for a transaction totalling $40,073.28. Following the completion of the sale, the executive vice president now directly owns 71,365 shares of the company's stock, valued at $528,814.65. Learn More on Ted Yednock's trading history.
Who are Annexon's active insiders?: Annexon's insider roster includes Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), and Ted Yednock (EVP). Learn More on Annexon's active insiders.
Are insiders buying or selling shares of Annexon?: During the last twelve months, Annexon insiders bought shares 5 times. They purchased a total of 16,000 shares worth more than $89,984.00. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 48,976 shares worth more than $224,444.81. The most recent insider tranaction occured on February, 18th when insider Jamie Dananberg sold 5,521 shares worth more than $16,342.16. Insiders at Annexon own 12.7% of the company. Learn More about insider trades at Annexon.
Information on this page was last updated on 2/18/2025.

Ted Yednock Insider Trading History at Annexon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/15/2024	Sell	5,408	$7.41	$40,073.28	71,365
9/19/2024	Sell	4,500	$7.10	$31,950.00	71,365
9/5/2024	Sell	5,500	$5.64	$31,020.00	10,000
8/29/2024	Sell	5,500	$5.95	$32,725.00	15,500
12/27/2023	Sell	21,000	$4.52	$94,920.00
9/13/2021	Sell	16,190	$20.00	$323,800.00	15,000
6/3/2021	Sell	15,000	$21.49	$322,350.00	15,000

Ted Yednock Buying and Selling Activity at Annexon

Annexon Company Overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Today's Range

Now: $2.25

$2.21

$2.31

50 Day Range

MA: $3.05

$2.24

$4.24

2 Week Range

Now: $2.25

$2.18

$7.85

Volume

1,086,710 shs

Average Volume

1,758,707 shs

Market Capitalization

$246.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Ted Yednock Biography and Net Worth

What is Ted Yednock's net worth?

How old is Ted Yednock?

What is Ted Yednock's salary?

How do I contact Ted Yednock?

Has Ted Yednock been buying or selling shares of Annexon?

Who are Annexon's active insiders?

Are insiders buying or selling shares of Annexon?